These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 19545786)
1. Efficacy of sunitinib and radiotherapy in genetically engineered mouse model of soft-tissue sarcoma. Yoon SS; Stangenberg L; Lee YJ; Rothrock C; Dreyfuss JM; Baek KH; Waterman PR; Nielsen GP; Weissleder R; Mahmood U; Park PJ; Jacks T; Dodd RD; Fisher CJ; Ryeom S; Kirsch DG Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1207-16. PubMed ID: 19545786 [TBL] [Abstract][Full Text] [Related]
2. Sunitinib suppresses tumor growth and metastases in a highly metastatic mouse mammary cancer model. Tanaka Y; Shibata MA; Morimoto J; Otsuki Y Anticancer Res; 2011 Apr; 31(4):1225-34. PubMed ID: 21508369 [TBL] [Abstract][Full Text] [Related]
3. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors. Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025 [TBL] [Abstract][Full Text] [Related]
4. Imaging biomarker dynamics in an intracranial murine glioma study of radiation and antiangiogenic therapy. Chung C; Jalali S; Foltz W; Burrell K; Wildgoose P; Lindsay P; Graves C; Camphausen K; Milosevic M; Jaffray D; Zadeh G; Ménard C Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):805-12. PubMed ID: 22929856 [TBL] [Abstract][Full Text] [Related]
5. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma. Bagi CM; Gebhard DF; Andresen CJ Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934 [TBL] [Abstract][Full Text] [Related]
6. Combining targeted agents with modern radiotherapy in soft tissue sarcomas. Wong P; Houghton P; Kirsch DG; Finkelstein SE; Monjazeb AM; Xu-Welliver M; Dicker AP; Ahmed M; Vikram B; Teicher BA; Coleman CN; Machtay M; Curran WJ; Wang D J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25326640 [TBL] [Abstract][Full Text] [Related]
7. Combined sunitinib and radiation therapy for preoperative treatment of soft tissue sarcoma: results of a phase I trial of the German interdisciplinary sarcoma group (GISG-03). Jakob J; Simeonova A; Kasper B; Ronellenfitsch U; Rauch G; Wenz F; Hohenberger P Radiat Oncol; 2016 Jun; 11():77. PubMed ID: 27255678 [TBL] [Abstract][Full Text] [Related]
8. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Patyna S; Laird AD; Mendel DB; O'farrell AM; Liang C; Guan H; Vojkovsky T; Vasile S; Wang X; Chen J; Grazzini M; Yang CY; Haznedar JO; Sukbuntherng J; Zhong WZ; Cherrington JM; Hu-Lowe D Mol Cancer Ther; 2006 Jul; 5(7):1774-82. PubMed ID: 16891463 [TBL] [Abstract][Full Text] [Related]
9. Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma. Huynh H; Ngo VC; Choo SP; Poon D; Koong HN; Thng CH; Toh HC; Zheng L; Ong LC; Jin Y; Song IC; Chang AP; Ong HS; Chung AY; Chow PK; Soo KC Curr Cancer Drug Targets; 2009 Sep; 9(6):738-47. PubMed ID: 19754358 [TBL] [Abstract][Full Text] [Related]
10. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Potapova O; Laird AD; Nannini MA; Barone A; Li G; Moss KG; Cherrington JM; Mendel DB Mol Cancer Ther; 2006 May; 5(5):1280-9. PubMed ID: 16731761 [TBL] [Abstract][Full Text] [Related]
11. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Ning S; Laird D; Cherrington JM; Knox SJ Radiat Res; 2002 Jan; 157(1):45-51. PubMed ID: 11754641 [TBL] [Abstract][Full Text] [Related]
12. Combined radiation therapy and sunitinib for preoperative treatment of soft tissue sarcoma. Jakob J; Simeonova A; Kasper B; Ronellenfitsch U; Wenz F; Hohenberger P Ann Surg Oncol; 2015 Sep; 22(9):2839-45. PubMed ID: 26085221 [TBL] [Abstract][Full Text] [Related]
13. Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis. Nguyen L; Fifis T; Christophi C BMC Cancer; 2016 Jul; 16():533. PubMed ID: 27460820 [TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. de Boüard S; Herlin P; Christensen JG; Lemoisson E; Gauduchon P; Raymond E; Guillamo JS Neuro Oncol; 2007 Oct; 9(4):412-23. PubMed ID: 17622648 [TBL] [Abstract][Full Text] [Related]
15. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. Pietras K; Hanahan D J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593 [TBL] [Abstract][Full Text] [Related]
18. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Stacchiotti S; Negri T; Zaffaroni N; Palassini E; Morosi C; Brich S; Conca E; Bozzi F; Cassinelli G; Gronchi A; Casali PG; Pilotti S Ann Oncol; 2011 Jul; 22(7):1682-1690. PubMed ID: 21242589 [TBL] [Abstract][Full Text] [Related]
19. SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. Laird AD; Christensen JG; Li G; Carver J; Smith K; Xin X; Moss KG; Louie SG; Mendel DB; Cherrington JM FASEB J; 2002 May; 16(7):681-90. PubMed ID: 11978732 [TBL] [Abstract][Full Text] [Related]
20. Necrosis of a skin autograft after short-term treatment with sunitinib in a 14-year-old girl with metastatic alveolar soft part sarcoma of the thigh. Hanzer M; Nebl A; Spendel S; Pilhatsch A; Urban C; Benesch M Klin Padiatr; 2010 May; 222(3):184-6. PubMed ID: 20514624 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]